MedTrace Logo

SYHX2011 in Combination With Carboplatin and Enlonstobart as First-Line Therapy for Squamous Non-Small Cell Lung Cancer

NCT07662811 · Status: NOT_YET_RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 396

Last updated 2026-06-29

No results posted yet for this study

Summary

Efficacy and Safety of SYHX2011 Combined with Carboplatin and Enlonstobart versus Nab-Paclitaxel Combined with Carboplatin and Tislelizumab as First-Line Treatment for Squamous Non-Small Cell Lung Cancer

Conditions

Interventions

DRUG

SYHX2011

SYHX2011:260 mg/m\^2, IV/30 ± 3 minutes(day1)

DRUG

Carboplatin

Carboplatin: AUC 5 mg/mL/min, IV/30\~60 minutes(day1)

DRUG

Enlonstobart

Enlonstobart: 360 mg, IV/60 minutes(day1)

DRUG

Nab-Paclitaxel

Nab-Paclitaxel: 260 mg/m\^2, IV/30 ± 3 minutes(day1)

DRUG

Carboplatin

Carboplatin: AUC 5 mg/mL/min, IV/30\~60 minutes(day1)

DRUG

Tislelizumab

Tislelizumab: 200 mg, IV/60 minutes(day1)

Sponsors & Collaborators

  • Shanghai Chest Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-01
Primary Completion
2027-12-31
Completion
2029-12-31

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07662811 on ClinicalTrials.gov